Québec, Canada (ots) - GenePOC, Inc. (GenePOC), a member of the Debiopharm Group, is proud to announce the launch of its 2nd assay this year, GenePOC(TM) GBS DS[1], for use on the revogene(TM) instrument. GenePOC GBS DS at intrapartum will aid to minimize the risk of GBS transmission from the mother to their ...
Waterloo, Ontario (ots/PRNewswire) - Intellijoint Surgical®, a medical technology company, is pleased to announce that it has received the approval of the CE Mark (Conformité Européenne) for its intellijoint HIP® System in Europe. A 3D Mini-Optical Navigation System, intellijoint HIP® provides surgeons with ...
Zurich, Switzerland (ots) - Sequana Medical AG (Sequana Medical), a commercial stage medical device company and an innovator in the management of liver disease, announces the publication of "Treatment of refractory ascites with an automated low-flow ascites pump in patients with cirrhosis", the results of the first ...
Bari, Italy (ots/PRNewswire) - - New production line for the aseptic filling of biotech medicines under isolator - Isolator technology represents best practice for the aseptic filling of injectable medicines and ensures the highest quality standards - Investment supports growth of Merck's portfolio of biotech medicines Merck, a leading science and technology company, ...
Hartford, Connecticut (ots/PRNewswire) - On October 1, 2017 RWS, the world's leading provider of translation, intellectual property, life sciences and language support services, announced a re-launch of its brand, website and divisional structure following a number of successful acquisitions which have significantly ...
Brussels (ots/PRNewswire) - - Taking Diabetes to Heart is a global online survey for people with type 2 diabetes to gain important insights about their awareness of cardiovascular disease (CVD) - Globally, CVD is the most common cause of death in people with type 2 diabetes[1] - Results from this survey will help ...
Lausanne (ots) - The 'JCA-Mauvernay Award 2017' is awarded to Doctors Yasuhiro Yamada and Hiroyoshi Nishikawa Debiopharm Group(TM) (Debiopharm - www.debiopharm.com), a Swiss-based global biopharmaceutical company, will be presenting the 'JCA-Mauvernay Award' on September 30 to Doctors Yasuhiro Yamada from the ...
Darmstadt, Germany and New York (ots/PRNewswire) - Not intended for US, Canadian and UK-based media - First-ever treatment indicated for curatively unresectable Merkel cell carcinoma (MCC) and first anti-PD-L1 to be available in Japan - Japanese Ministry of Health, Labour and Welfare (MHLW) decision based on Javelin Merkel 200 study, the largest registrational trial for an immunotherapy in MCC - First Asian approval for ...
Sunnyvale, California (ots/PRNewswire) - First Study to Evaluate the Use of Stereotactic Body Radiation Therapy in Low-Risk Prostate Cancer 10 Years Post Treatment Accuray Incorporated (NASDAQ: ARAY) announced today that data from a prospective study of 230 men with low-risk prostate cancer showed 98.4 percent had ...
Québec City (ots/PRNewswire) - The first plant-based seasonal flu vaccine candidate reaches final clinical stage Medicago, a Canadian biopharmaceutical company and leader in the development and production of plant-based vaccines and therapeutics, is proud to announce the start of a Phase 3 efficacy study for its seasonal quadrivalent influenza vaccine (QIV) candidate. ...
Darmstadt, Germany, and New York, Usa (ots/PRNewswire) - Not intended for US, Canadian and UK-based media - First approved immunotherapy for rare and aggressive skin cancer in the European Union, with initial launches planned in Germany and the UK - Builds on Bavencio's previous accelerated approvals in the US and recent approval in Switzerland - Approval is based on ...
Sunnyvale, California (ots/PRNewswire) - Accuray Incorporated (NASDAQ: ARAY) announced today that data and first-hand experience with its advanced CyberKnife® and Radixact(TM) Systems (http://www.accuray.com/product-overview) , and unique software solutions, will be shared by leading radiation oncology practitioners at the 2017 ASTRO (American Society for Radiation Oncology) Annual Meeting in San Diego, California from ...
Reykjavik, Iceland (ots/PRNewswire) - - The generation of new mutations is a key driver of evolution but also of susceptibility to rare diseases - Fathers pass on four times as many new mutations as mothers do, but the maternal contribution is particularly strong in 10% of the genome that is prone to double-strand breaks in the helix structure of DNA - These regions have been mutational hotspots for a very long time, and ...
Lausanne, Switzerland (ots/PRNewswire) - Today, the results of a pooled analysis of four Galderma-sponsored studies evaluating the use of topical therapies for the treatment of inflammatory papules and pustules of rosacea were presented at the 26th European Academy of Dermatology and Venereology Congress in Geneva, Switzerland. The success of rosacea treatment is ...
Lisbon, Portugal (ots/PRNewswire) - Symposium: S33 Novo Nordisk today announced new analyses from the multinational, double-blinded DEVOTE trial showing that people with type 2 diabetes who experience severe hypoglycaemia (low blood sugar levels) are at greater risk of death. The risk was four-fold higher 15 days ...
Lisbon, Portugal (ots/PRNewswire) - Oral Presentation 113 In people with type 2 diabetes, Xultophy® (insulin degludec/liraglutide) significantly reduced a number of risk factors associated with an increased risk of cardiovascular disease (CVD), compared to basal insulin.[1] According to a new post-hoc analysis presented today at the 53rd Annual Meeting of the European ...
Lisbon, Portugal (ots/PRNewswire) - Poster # 820 A post-hoc analysis of the SUSTAIN 1-5 trials demonstrated that a greater proportion of adults with type 2 diabetes achieved a clinically meaningful reduction in both HbA1c and body weight with once-weekly semaglutide vs. comparator treatments. Comparators included ...
Lisbon, Portugal (ots/PRNewswire) - Fiasp® (fast-acting insulin aspart), the only approved, new-generation, ultra-fast acting[1]-[3] mealtime insulin, improved overall blood sugar (HbA1c) and post-meal sugar (postprandial glucose or PPG) control over 52 weeks, compared to conventional insulin aspart (NovoRapid®), in new study findings[4]. (Logo: ...
Teva Pharmaceuticals Europe BV
Amsterdam (ots/PRNewswire) - ONLY FOR PAN-EUROPEAN/ EUROPEAN ENGLISH LANGUAGE MEDICAL TRADE MEDIA Study Highlights Improved Outcomes for Asthma Patients Including Fewer Exacerbations Following Change in Treatment to DuoResp Spiromax® Teva Pharmaceuticals Europe B.V., (NYSE and TASE: TEVA) today announced data from ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.K./U.S. based media - Big data platform to help accelerate innovative discovery, development and delivery of new approaches in cancer care - Enhanced analytical capabilities to better define personalized treatment options and help predict treatment outcomes - Focused on areas of high unmet need to help enhance ...
Cambridge, England (ots/PRNewswire) - - First presentation of largest ever real-world flutiform® study at European Respiratory Society International Congress involving over 2,500 patients - Proportion of patients with well-controlled asthma more than doubled 12 months after switching to flutiform pMDI New ...
Lausanne, Switzerland (ots/PRNewswire) - Today, the results of a study evaluating the combined use of topical rosacea treatments ivermectin 1% cream and brimonidine 0.33% gel were published in the Journal of Drugs in Dermatology. (Logo: http://mma.prnewswire.com/media/554005/Galderma_Logo.jpg ) "This is the first ...
Cork, Ireland (ots/PRNewswire) - - Viral Hepatitis Research and Development to Focus on Addressing Significant Unmet Needs in Chronic Hepatitis B Janssen Sciences Ireland UC (Janssen), today announced a strategic decision to discontinue further development of the investigational hepatitis C treatment regimen JNJ-4178, a combination of three direct acting antivirals - AL-335, odalasvir and simeprevir. The ongoing phase II ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK/U.S. based media - EUR1 million grant funded by Merck supports research with the potential to advance implementation of personalized treatment for solid tumors - Three winners selected from 100 scientifically diverse applicants worldwide Merck, a leading ...
Cambridge, England (ots/PRNewswire) - - flutiform k-haler achieved high levels of lung deposition of over 44% of delivered dose - Plume force of flutiform k-haler was compared with fluticasone propionate/salmeterol xinafoate delivered via the Seretide® Evohaler® pMDI and Sirdupla® pMDI devices - Pharmacokinetic ...
Beerse, Belgium (ots/PRNewswire) - Janssen announces results of pan-European research which shows that a third of psychiatrists (34%) delay conversations about the full range of treatment options with their patients living with schizophrenia. The 'Open Minds' survey, conducted among 347 psychiatrists across eight ...
Tokyo and Cambridge, England (ots/PRNewswire) - SciBite - The award-winning semantic analytics company, today announced that GlaxoSmithKline K.K. (hereinafter referred to as GSK Japan), one of Japan's leading research-based pharmaceutical and healthcare companies, has selected SciBite's Semantic Platform to enhance ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK-based media - Data to showcase Merck KGaA, Darmstadt, Germany's strong and diverse pipeline ranging from immuno-oncology to DNA damage response - Avelumab data validate potential in hard-to-treat cancers and highlight progress of the JAVELIN clinical ...
Darmstadt, Germany (ots/PRNewswire) - Not intended for U.K. or U.S. based media ESMO 2017 abstract # Erbitux®: 576P, 593P, 1068P, 1579P; avelumab: 1227P, 913P, 1377TiP, 882P, 856P; M6620 (ATR inhibitor): 242PD; M2698 (dual p70S6K/Akt inhibitor): 370PD, 393P; tepotinib (c-Met kinase inhibitor): 701P - Data to showcase Merck's strong and diverse pipeline ranging from ...